Orchestra BioMed

Public

Orchestra BioMed is a biomedical innovation company that accelerates high-impact medical technologies through risk-reward sharing partnerships with leading medical device companies. Its lead programs are BackBeat Cardiac Neuromodulation Therapy for hypertension treatment in pacemaker patients and Virtue Sirolimus AngioInfusion Balloon for atherosclerotic artery disease. The company has strategic partnerships with Medtronic and Terumo Corporation.

Founders David Hochman

CEO David Hochman

Company

Founded

2018

Headquarters

New Hope, United States

Financials

Total Funding

$185M

Public Market

Exchange

NASDAQ

Ticker

OBIO

IPO Date

Jan 27, 2023

Sectors

Biotech

www.orchestrabiomed.com Twitter

Funding History

3 rounds

IPO Jan 27, 2023

NASDAQ: OBIO

Series D Jul 5, 2022

$110M

Medtronic RTW Investments Perceptive Advisors Terumo Corporation SternAegis Ventures

Series B Jul 10, 2019

$34M

Perceptive Advisors RTW Investments (Lead) Soleus Capital (Lead) Terumo Corporation SternAegis Ventures

Undisclosed Nov 15, 2018

$41M

SternAegis Ventures

Funding data is compiled from multiple independent sources including company announcements, press coverage, and regulatory filings. While we strive for accuracy, amounts and dates may reflect reported figures at time of announcement.